SCHEMBL6508895

SCHEMBL6508895

Cc1n[nH]c2c1c(=O)n(CC(N)Cc1ccccc1)c1ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
KDM4E B2RXH2 2/20 0.35
CYP2C9 P11712 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
PLK1 P53350 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21067780 0.81 CYP1A2 (0.48) MEN1KMT2AMAPK1SMN1; SMN2CYP1A2
SCHEMBL6514910 0.78 CHEK1 (0.49) MAPK1CYP1A2KDM4EHSD17B10TDP1
SCHEMBL6521770 0.76 HDAC3 (0.40) MEN1KMT2ASMN1; SMN2KDM4EHSD17B10
SCHEMBL6515436 0.76 CHEK1 (0.51) KDM4ETDP1PLK1ALDH1A1HPGD
SCHEMBL6518602 0.76 AURKA (0.41) MEN1KMT2ACYP1A2CYP2C19KDM4E
SCHEMBL6518571 0.74 HDAC3 (0.41) MEN1KMT2AKDM4EHPGDPOLB
SCHEMBL6508661 0.74 TOP2A (0.53) SMN1; SMN2KDM4ETDP1PLK1MAPT
SCHEMBL6523698 0.74 TSHR (0.47) KDM4ETDP1ALDH1A1HPGDPOLB
Hydrochloric Acid SCHEMBL6518743 0.73 TOP2A (0.52) SMN1; SMN2KDM4EMAPTAURKAKDR
SCHEMBL6514357 0.72 ALDH1A1 (0.44) MEN1KMT2AL3MBTL1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 MEN1 1973/4885KMT2A 1919/4885MAPK1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.